VALNEVA SE SP.ADS/2 Net Assets
VALNEVA SE SP.ADS/2 net assets. Based on the latest financial reports, VALNEVA SE SP.ADS/2 (AYJ0) has net assets worth €81.12 Million EUR (≈ $94.84 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€388.28 Million ≈ $453.94 Million USD) and total liabilities (€307.15 Million ≈ $359.10 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore VALNEVA SE SP.ADS/2 net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €81.12 Million |
| % of Total Assets | 20.89% |
| Annual Growth Rate | -11.18% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 38.57 |
Net Assets of VALNEVA SE SP.ADS/2 (2021–2025)
Net assets of VALNEVA SE SP.ADS/2 from 2021 to 2025. This chart illustrates how VALNEVA SE SP.ADS/2's net assets have evolved over time, based on quarterly financial data. See VALNEVA SE SP.ADS/2 (AYJ0) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for VALNEVA SE SP.ADS/2 (2021–2025)
The table below shows the annual net assets of VALNEVA SE SP.ADS/2 from 2021 to 2025. For live market cap and overall valuation, see VALNEVA SE SP.ADS/2 market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €106.17 Million ≈ $124.12 Million |
-41.43% |
| 2024-12-31 | €181.25 Million ≈ $211.90 Million |
+41.33% |
| 2023-12-31 | €128.25 Million ≈ $149.93 Million |
-41.65% |
| 2022-12-31 | €219.80 Million ≈ $256.97 Million |
+28.85% |
| 2021-12-31 | €170.58 Million ≈ $199.43 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to VALNEVA SE SP.ADS/2's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 37214600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
VALNEVA SE SP.ADS/2 Net Assets Breakdown (December 2025)
VALNEVA SE SP.ADS/2 net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €785.29 Million | 739.67% |
| Total Equity | €106.17 Million | 100.00% |
VALNEVA SE SP.ADS/2 Competitors by Market Cap
The table below lists competitors of VALNEVA SE SP.ADS/2 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Eson Precision Ind Co Ltd
TW:5243
|
$474.15 Million |
|
Datamatics Global Services Limited
NSE:DATAMATICS
|
$474.17 Million |
|
El Pollo Loco Holdings Inc
NASDAQ:LOCO
|
$474.19 Million |
|
Ooma Inc
NYSE:OOMA
|
$474.22 Million |
|
Malam Team
TA:MLTM
|
$474.06 Million |
|
Gresgying Digital Energy Technology Co Ltd
SHG:600212
|
$473.98 Million |
|
Shanghai Kinlita Chemical Co
SHE:300225
|
$473.77 Million |
|
Juniper Hotels Ltd
NSE:JUNIPER
|
$473.60 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in VALNEVA SE SP.ADS/2's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 181,253,000 to 106,168,000, a change of -75,085,000 (-41.4%).
- Net loss of 115,192,000 reduced equity.
- Other factors increased equity by 40,107,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-115.19 Million | -108.5% |
| Other Changes | €40.11 Million | +37.78% |
| Total Change | €- | -41.43% |
Book Value vs Market Value Analysis
This analysis compares VALNEVA SE SP.ADS/2's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.48x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.82x to 7.48x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €1.62 | €4.58 | x |
| 2022-12-31 | €1.59 | €4.58 | x |
| 2023-12-31 | €0.92 | €4.58 | x |
| 2024-12-31 | €1.12 | €4.58 | x |
| 2025-12-31 | €0.61 | €4.58 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently VALNEVA SE SP.ADS/2 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -108.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -65.95%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 3.76x
- Recent ROE (-108.50%) is below the historical average (-60.52%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -43.04% | -21.09% | 0.43x | 4.79x | €-90.48 Million |
| 2022 | -65.19% | -39.66% | 0.58x | 2.83x | €-165.26 Million |
| 2023 | -79.09% | -65.99% | 0.33x | 3.59x | €-114.25 Million |
| 2024 | -6.76% | -7.22% | 0.34x | 2.76x | €-30.37 Million |
| 2025 | -108.50% | -65.95% | 0.44x | 3.76x | €-125.81 Million |
Industry Comparison
This section compares VALNEVA SE SP.ADS/2's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,369,067
- Average return on equity (ROE) among peers: -55.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| VALNEVA SE SP.ADS/2 (AYJ0) | €81.12 Million | -43.04% | 3.79x | $474.12 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $4.50 Million | -321.01% | 1.17x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-51.59 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $141.97 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $63.37 Million | -33.73% | 0.67x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $277.18 Million | -3.32% | 0.01x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $714.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
About VALNEVA SE SP.ADS/2
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile t… Read more